N/A (device / behavioral)RecruitingNCT07254364

Sweat and interstitial insulin sensing — early wearable research

What this study tests

A Texas A&M basic-science study of insulin measurement in sweat and interstitial fluid. The registry targets 92 participants and lists recruiting in its August 2026 update, but an older posted consent describes 32 healthy volunteers. No results are posted; this does not establish a noninvasive glucose-monitoring replacement.

Editorial review: 2026-09-17. 16 September review-note archive (earlier notes may not cover later changes).

Registry checked: 2026-09-17. Registry’s own update: 2026-08-28.

Most recent recorded citation date: 2026-08-28. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. Review coverage and open work · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?: Current registry structured ages are 18–90, with BMI 18–35 and T1D-specific inclusion wording; healthy volunteers are also marked eligible. The older consent instead describes healthy adults 18–30 or 50–75 with BMI 22–35. Enrollment criteria require clarification by the study team. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results: No results posted in the registry as checked 17 September 2026. Enrollment figures are planned targets, not observed outcomes.Read the result sources and their limitations →
Important harms: Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval: Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?: Read the 16 September review-note archive and current review coverage. Later changes and new records may not appear in the earlier notes. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

Time-varying plasma insulin concentrations and their relationship with sweat and dermal interstitial-fluid measurements, over up to 9 hours on one study day

The full picture

Research question

This Texas A&M study aims to quantify insulin, rather than glucose, in sweat and compare it with measurements in dermal interstitial fluid and blood. Its registered design is an unmasked, basic-science interventional study with a crossover designation and a target of 92 participants. Six standardized meal formulations are listed, but these are not six demonstrated treatment benefits. No sensor accuracy, insulin-correlation or clinical outcome results are posted.¹

Procedures and risks

The registry describes stimulated sweat collection, a forearm microneedle patch and repeated blood sampling around a liquid meal. The aim of noninvasive sweat measurement does not make all research procedures noninvasive, and this is not evidence that the device can replace a glucose CGM or guide insulin dosing. The older posted consent says there is no direct participant benefit. It lists risks including catheter-related bruising or infection, skin reactions and gastrointestinal symptoms from the meal; these are disclosed potential risks, not observed event rates.¹²

Conflicting population descriptions

The registry last updated 28 August 2026 estimates 92 participants and structured ages 18–90. Its criteria give BMI 18–35 and T1D-specific wording, while also marking healthy volunteers eligible. The posted consent approved 25 June 2025 instead describes 32 healthy participants, divided between ages 18–30 and 50–75, with BMI 22–35. These descriptions cannot be treated as one confirmed enrollment population. The research team must clarify which version and cohort apply.¹²

Status and timing

The registry lists recruiting at Texas A&M in College Station, with an actual start of 11 September 2025 and estimated completion in December 2026. These are registry statements checked 17 September 2026; a current individual place in the study has not been confirmed. The institution is the registered sponsor, and the older consent identifies USDA Agricultural Research Service support.¹²

ClinicalTrials.gov. NCT07254364, last posted update 2026-08-28; checked 17 September 2026. https://clinicaltrials.gov/study/NCT07254364 ↩ ↩² ↩³ ↩⁴
Original posted consent, IRB approval 25 June 2025, pages 1–7. https://cdn.clinicaltrials.gov/large-docs/64/NCT07254364/ICF_000.pdf ↩ ↩² ↩³

Sources

[1]NCT07254364 — Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring · Trial registry · 2026-08-28 — Original registry description and structured fields checked 17 September 2026; no posted results. Recruitment and estimated dates are registry statements, not direct site confirmation.
[2]Posted informed-consent form for insulin sensing research · Trial registry — Original eight-page consent, IRB approval dated 25 June 2025. Population and target differ from the later registry: 32 healthy participants versus estimated 92 in the August 2026 record. It is not confirmed as the current consent for every cohort.